CLL trial data for Venclyxto (venetoclax) plus Gazyvaro (obinutuzumab) is shared by Roche and AbbVie in the New England Journal of Medicine. The trial was done in patients who had untreated chronic lymphocytic leukemia.
The primary endpoint for investigator-assessed progression-free survival was met during the pivotal phase III study. It was a fixed 12 month study, which depicts 65% reduction in chances of disease worsening or death in comparison to current treatment of Gazyvaro plus chlorambucil.
A median follow-up after 28 months depicts that the overall response rate of 84.7% was observed in patients who received chemotherapy-free combination. One year following the stopping treatment, about 88.2% patients remained progression-free in comparison to 64.1% during Gazyvaro plus chlorambucil arm treatment.
The outcomes obtained during CLL14 Phase III trials represent a major advancement to improvise the results during chronic lymphocytic leukaemia.
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like